Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K ...

PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a biopharmaceutical company specializing in cardiovascular therapies with a market capitalization of $35.2 million and impressive 210% ...

Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

Oral anticoagulant or antiplatelet medication use had no substantial effect on the accuracy of multitarget stool DNA testing for colorectal cancer, according to a study published in Gastro Hep ...

Pharmacists may use these common misconceptions to target education on proper epistaxis management. Patients responded positively to education, often wanting to share stories and ask questions.

The stock is trading at a bargain-bin valuation, especially compared to its chief peers. The strong Target brand and extensive store network could help it push through current challenges to thrive ...

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.